Undisclosed KRAS 12D inhibitor / SK Bio - LARVOL DELTA

SK Biopharm Announces KRAS G12D Inhibitor Research Results at the American Cancer Research Association [Google translation] (BioTimes) - "The results confirmed a strong anti-tumor effect when the inhibitor was orally administered to an animal model of KRAS G12D mutant pancreatic cancer (PDAC), and no significant side effects such as weight loss were observed. According to the study, this inhibitor showed high selectivity and strong binding affinity for KRAS G12D, and strongly inhibited the proliferation of cancer cell lines with the mutation. On the other hand, it showed a 50-1,000-fold lower proliferation inhibition effect on other KRAS mutations, and its effect on normal cell growth was confirmed to be minimal. In particular, it showed a superior plasma exposure level compared to the KRAS G12D inhibitor candidates reported so far, and also showed excellent performance in oral bioavailability, and effectively inhibited pERK (phosphorylated ERK) in tumor tissues even at low concentrations."

Preclinical • Pancreatic Ductal Adenocarcinoma